Implications of Immunotherapy for Pediatric Malignancies: A Summary from the APSA Cancer Committee
Talbot L, Lautz T, Aldrink J, Ehrlich P, Dasgupta R, Mattei P, Tracy E, Glick R, Grant C, Brown E, Christison-Lagay E, Rodeberg D. Implications of Immunotherapy for Pediatric Malignancies: A Summary from the APSA Cancer Committee. Journal Of Pediatric Surgery 2023, 58: 2119-2127. PMID: 37550134, DOI: 10.1016/j.jpedsurg.2023.07.001.Peer-Reviewed Original ResearchAPSA Cancer CommitteeClass of immunotherapyT-cell therapyCancer CommitteePediatric malignanciesChimeric antigen receptor T-cell therapyMonoclonal antibody checkpoint inhibitorsTransgenic T cell receptorBispecific T-cell engagersCell therapyEarly phase clinical trialsYoung adultsConventional chemotherapeutic regimensDisease-related deathT-cell engagersClass of therapyT cell receptorCare of childrenCheckpoint inhibitorsAdverse eventsMetastatic diseaseSystemic treatmentChemotherapeutic regimensSurgical interventionClinical trials